Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Initiates PII Study of Bardoxolone Methyl in Japan
March 6, 2015
- Opdivo Approved for Lung Cancer in US
March 6, 2015
- Pfizer Japan Sales Down 5% as Generic Erosion Weighs
March 5, 2015
- Merck Japan Names Ralf Annasentz as New President
March 5, 2015
- Sanwa Kagaku to Promote Katsumi Hata as New President
March 5, 2015
- Toray Files Remitch Capsules for Pruritus in Chronic Liver Disease
March 5, 2015
- GSK, Novartis Unveil Details of 3-Part Asset Swap Deal in Japan
March 4, 2015
- Weber to Become CEO of Takeda in April
March 4, 2015
- Announcement: 12th Annual BIO Asia International Conference to Be Held on March 24, 25
March 4, 2015
- Japan Units of Abbott, Mylan to Run Separate Operations for Now
March 4, 2015
- Almac Aims to Expand Japan Business
March 4, 2015
- Santen Files Sirolimus for Noninfectious Uveitis in Europe
March 4, 2015
- Chugai, Athersys Join Hands for Cell Therapy Treatment
March 4, 2015
- Taiho Files Lonsurf for EU Approval
March 4, 2015
- Torii to Market 2 Anti-HIV Drugs Containing Tenofovir Alafenamide in Japan
March 3, 2015
- Switch OTC Drug Market Grows to 162 Billion Yen in 2014: Fuji Keizai
March 3, 2015
- Novartis Offers Apologies over Biz Suspension, Vows to Prevent Recurrence
March 2, 2015
- Jinarc Approved for Autosomal Dominant Polycystic Kidney Disease in Canada: Otsuka
March 2, 2015
- Eli Lilly Aims to Lead Japan Diabetes Market by 2020
March 2, 2015
- MTPC Eyes Total Sales of Over 100 Billion Yen for Remicade, Simponi
February 27, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…